GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (FRA:R3I1) » Definitions » Cash Flow from Financing

Advanced Oncotherapy (FRA:R3I1) Cash Flow from Financing : €46.79 Mil (TTM As of Jun. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Advanced Oncotherapy Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2022, Advanced Oncotherapy received €12.40 Mil more from issuing new shares than it paid to buy back shares. It received €1.75 Mil from issuing more debt. It paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received €0.00 Mil from paying cash dividends to shareholders. It spent €0.19 Mil on other financial activities. In all, Advanced Oncotherapy earned €13.96 Mil on financial activities for the six months ended in Jun. 2022.


Advanced Oncotherapy Cash Flow from Financing Historical Data

The historical data trend for Advanced Oncotherapy's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy Cash Flow from Financing Chart

Advanced Oncotherapy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.98 16.31 43.99 29.54 48.00

Advanced Oncotherapy Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.35 14.28 13.52 34.33 12.46

Advanced Oncotherapy Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Advanced Oncotherapy's Cash from Financing for the fiscal year that ended in Dec. 2021 is calculated as:

Advanced Oncotherapy's Cash from Financing for the quarter that ended in Jun. 2022 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was €46.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Oncotherapy  (FRA:R3I1) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Advanced Oncotherapy's issuance of stock for the six months ended in Jun. 2022 was €12.40 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Advanced Oncotherapy's repurchase of stock for the six months ended in Jun. 2022 was €0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Advanced Oncotherapy's net issuance of debt for the six months ended in Jun. 2022 was €1.75 Mil. Advanced Oncotherapy received €1.75 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Advanced Oncotherapy's net issuance of preferred for the six months ended in Jun. 2022 was €0.00 Mil. Advanced Oncotherapy paid €0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Advanced Oncotherapy's cash flow for dividends for the six months ended in Jun. 2022 was €0.00 Mil. Advanced Oncotherapy received €0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Advanced Oncotherapy's other financing for the six months ended in Jun. 2022 was €-0.19 Mil. Advanced Oncotherapy spent €0.19 Mil on other financial activities.


Advanced Oncotherapy Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Oncotherapy (FRA:R3I1) Business Description

Traded in Other Exchanges
N/A
Address
4 Tenterden Street, Third Floor, London, GBR, W1S 1TE
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.

Advanced Oncotherapy (FRA:R3I1) Headlines

No Headlines